The EFHD1 Knockout A2780 Polyclonal Cells constitute a CRISPR/Cas9-edited heterogeneous knockout population derived from the A2780 human ovarian carcinoma cell line. This knockout product provides a loss-of-function model for EFHD1 (mitocalcin), a mitochondrial calcium-binding protein, without clonal selection. The polyclonal format preserves genetic diversity, minimizing clone-specific artifacts while enabling population-level phenotypic analyses. Comparative studies with parental A2780 cells allow dissection of EFHD1-dependent mitochondrial calcium signaling and apoptosis pathways.
The A2780 cell line, derived from an untreated endometrioid adenocarcinoma, is a classic epithelial ovarian cancer model widely used in cisplatin resistance research. Its intact apoptotic machinery and drug sensitivity make it ideal for studying mitochondrial apoptosis. Coupled with EFHD1 knockout, this model provides a clinically relevant platform to explore mechanisms of chemotherapy-induced cell death.
EFHD1 is a mitochondrial calcium sensor with EF-hand domains that interacts with VDAC, ANT, and cyclophilin D to regulate mPTP opening. Upstream regulators include cytosolic calcium, oxidative stress, and BCL2 proteins. Upon calcium binding, EFHD1 promotes cytochrome c release, activating caspase-9 and caspase-3, leading to apoptosis. Knockout impairs mitochondrial calcium buffering, disrupts mPTP dynamics, and may promote survival under stress.
In A2780 cells, EFHD1 knockout allows investigation of mitochondrial calcium handling in chemoresistance. As cisplatin and other agents rely on intrinsic apoptosis, EFHD1 disruption could confer resistance. This model aids studies of mitochondrial dysfunction in ovarian cancer and beyond, given EFHD1??s emerging role in neurodegeneration and cardiovascular disease.
Applications include western blotting for knockout validation, Annexin V/PI apoptosis assays, JC-1 mitochondrial potential measurement, and Rhod-2 AM calcium imaging. Colony formation and cisplatin sensitivity assays assess chemoresistance. These cells also enable screening of mPTP modulators or BH3 mimetics. For further information or to discuss customization options, please contact Ascent Research.
